The delay, narrowed approval, and extra study steps raise concerns about the status of and potential added requirements for other COVID vaccines.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
The ECDC says a third dose should already be considered in the immune-compromised.
"A transparent, thorough, and objective review of the data by the FDA is critical."
The rheumatoid arthritis drug baricitinib was shown to reduce mortality in hospitalized COVID-19 patients, according to a randomized, controlled trial published in The Lancet Respiratory Medicine yesterday. Baricitinib acts as a Janus kinases inhibitor and is under emergency use authorization to treat severe COVID-19 by the US Food and Drug Administration.
Even those who had mild COVID-19 are at increased risk for major declines in kidney function.
August was the fourth-worst month of the pandemic for new COVID-19 cases.
Pre-hospital antiplatelet therapy, most commonly aspirin, was associated with significantly lower in-hospital mortality rates for COVID-19 patients, according to a study this week in the Journal of Thrombosis and Haemostasis.
Parents are split on whether mask mandates belong in schools, and colleges grapple with vaccine mandates.
Wealthy nations have shipped less than 10% of the requested 1 billion doses by September.
Residents of states that lifted eviction bans were at an 83% higher risk for COVID-19 after 12 weeks.
After two doses of an mRNA-based COVID-19 vaccine, nearly 90% of immunocompromised patients had an antibody response, but it was about as third as strong as those with healthy immune systems, according to data published in the Annals of Internal Medicine yesterday.
